今开:0.0 | 昨收:108.24 |
最高:0.0 | 最低:0.0 |
涨停价:0.0 | 跌停价:0.0 |
总市值:7.7035975315E10 |
$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792 Size: 69 KB 网页链接
$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796 Size: 42 KB 网页链接
$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527 Act: 34 Size: 15 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217 Act: 33 Size: 39 KB 网页链接